# US 2021/0330756 A1 · Acetylation of Miro1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330756 A1
- Document ID: US20210330756A1
- Status: Published application
- Kind: A1
- Application number: 17/188,139
- Filed: 2021-03-01
- Published: 2021-10-28
- Earliest claimed: 2020-04-28
- Assignees: University of South Carolina
- Applicants: University of South Carolina
- Inventors: Jeffery L. Twiss; Amar N. Kar
- Web page: https://patentgrep.com/patent/US20210330756A1

## CPC

- A61K 38/46: Hydrolases (3)
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- C07K 16/18: against material from animals or humans
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 16/40: against enzymes
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12Y 306/05: acting on GTP; involved in cellular and subcellular movement (3.6.5)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Deacetylation of rat Miro1 on Lysine 105 attenuates axon growth on non-permissive substrates by making mitochondria more sensitive to Ca levels, depolarizing mitochondrial membranes and blocking mitochondrial transport; the current disclosure provides an antibody that specifically recognizes the lysine 105 acetylated and not the deacetylated Miro1 protein.

## Claims

### Claim 1

A method for supporting axon growth comprising:
sustaining mitochondrial transport and mitochondrial membrane potential in a presence of CNS axon growth inhibitors via administering acetyl-Miro1; and
inhibiting histone deacetylase 6 (HDAC6).

### Claim 2 (depends on 1)

The method of claim 1 wherein, supporting axon growth occurs in adult dorsal root ganglion.

### Claim 3 (depends on 1)

The method of claim 1 wherein, the method inhibits histone deacetylase 6 (HDAC6) having Sequence Listing No. 1.

### Claim 4 (depends on 3)

The method of claim 3 wherein, tubastatin (TubA) is administered to inhibit HDAC6.

### Claim 5 (depends on 1)

The method of claim 1 wherein, nerves treated via the method show increased mitochondrial numbers in unmyelinated axons.

### Claim 6 (depends on 1)

The method of claim 1 wherein, in nerves treated via the method a ratio of anterogradely to retrogradely moving axonal mitochondria increases.

### Claim 7 (depends on 1)

The method of claim 1 wherein, the method prevents decreased mitochondrial transport in axons caused by released Ca2+.

### Claim 8 (depends on 1)

The method of claim 1, wherein Miro1. comprises Sequence Listing No. 2.

### Claim 9

A method for protecting axons from mitochondrial damage comprising:
administering tubastatin (TubA) to axons; and
wherein administration of TubA inhibits histone deacetylase 6 (HDAC6).

### Claim 10 (depends on 9)

The method of claim 9, wherein the protected axons are distal axons.

### Claim 11 (depends on 9)

The method of claim 9, wherein the protected axons are proximal axons.

### Claim 12 (depends on 9)

The method of claim 9, wherein treatment with TubA expands growth size and alters mitochondrial transport.

### Claim 13 (depends on 9)

The method of claim 9, wherein treated axons show no growth cone retraction after treatment with TubA.

### Claim 14 (depends on 9)

The method of claim 9, wherein the method causes increased anterograde movement of axonal mitochondria.

### Claim 15 (depends on 9)

The method of claim 9, wherein the method prevents axon retraction and end bulb formation in distal axons.

### Claim 16 (depends on 9)

The method of claim 9, wherein the method increases membrane potential in mitochondria of axons.

### Claim 17 (depends on 9)

The method of claim 9, wherein the method prevents decreased mitochondrial transport in axons caused by released Ca2+.

### Claim 18 (depends on 9)

The method of claim 9, wherein the method acetylates Miro1. having Sequence Listing No. 2.
